Antitussive offers convenient twice-daily dosing
July 26th 2004The FDA recently approved codeine/chlorpheniramine (Codeprex, Celltech Group) extended-release suspension (CIII) for the temporary relief of cough, as may occur with the common cold or inhaled irritants, and for the temporary relief of runny nose; sneezing; itching of the nose or throat; and itchy, watery eyes due to hay fever, other upper respiratory allergies, or allergic rhinitis. The product is expected to be available in retail pharmacies by the fourth quarter.
Antimicrobial offers improved safety and tolerability
July 26th 2004Trichomoniasis is a sexually transmitted disease with potentially serious sequelae. Fortunately, clinicians will soon be able to offer patients with this condition a new molecular entity. The FDA recently approved tinidazole (Tindamax, Presutti Laboratories) for the treatment of trichomoniasis caused by Trichomonas vaginalis in both female and male patients; giardiasis caused by Giardia duodenalis (also called G. lamblia) in both adults and pediatric patients older than three years of age; and amebiasis and amebic liver abscess caused by Entamoeba histolytica in adults and children older than three years of age. Tinidazole will be available in pharmacies sometime this month
Women have new patch for preventing osteoporosis
July 12th 2004Clinicians will soon be able to offer postmenopausal women transdermal estrogen therapy that delivers half the dose of the lowest currently available dose of transdermal estrogen. The FDA recently approved estradiol transdermal system (Menostar, Berlex) 14 mcg/d for the prevention of postmenopausal osteoporosis. The product will be available later this summer.
New glaucoma drug offers convenient once-daily dosing
July 12th 2004The FDA recently approved timolol (Istalol, ISTA Pharmaceuticals) ophthalmic solution 0.5% for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The product will be available within the next several months.